Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Neuroscience ; 290: 594-607, 2015 Apr 02.
Article in English | MEDLINE | ID: mdl-25637802

ABSTRACT

Modulation of corticostriatal synaptic activity by dopamine is required for normal sensorimotor behaviors. After loss of nigrostriatal dopamine axons in Parkinson's disease, l-3,4-dihydroxyphenlalanine (l-DOPA) and dopamine D2-like receptor agonists are used as replacement therapy, although these drugs also trigger sensitized sensorimotor responses including dyskinesias and impulse control disorders. In mice, we lesioned dopamine projections to the left dorsal striatum and assayed unilateral sensorimotor deficits with the corridor test as well as presynaptic corticostriatal activity with the synaptic vesicle probe, FM1-43. Sham-lesioned mice acquired food equivalently on both sides, while D2 receptor activation filtered the less active corticostriatal terminals, a response that required coincident co-activation of mGlu-R5 metabotropic glutamate and CB1 endocannabinoid receptors. Lesioned mice did not acquire food from their right, but overused that side following treatment with l-DOPA. Synaptic filtering on the lesioned side was abolished by either l-DOPA or a D2 receptor agonist, but when combined with a CB1 receptor antagonist, l-DOPA or D2 agonists normalized both synaptic filtering and behavior. Thus, high-pass filtering of corticostriatal synapses by the coordinated activation of D2, mGlu-R5, and CB1 receptors is required for normal sensorimotor response to environmental cues.


Subject(s)
Cerebral Cortex/physiopathology , Corpus Striatum/physiopathology , Dopamine/metabolism , Motor Activity/physiology , Parkinsonian Disorders/physiopathology , Synapses/physiology , Animals , Cerebral Cortex/drug effects , Corpus Striatum/drug effects , Dopamine Agents/pharmacology , Levodopa/pharmacology , Mice, Inbred C57BL , Motor Activity/drug effects , Neural Pathways/drug effects , Neural Pathways/physiopathology , Oxidopamine , Parkinsonian Disorders/drug therapy , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Receptor, Cannabinoid, CB1/metabolism , Receptor, Metabotropic Glutamate 5/metabolism , Receptors, Dopamine D2/agonists , Receptors, Dopamine D2/metabolism , Synapses/drug effects , Tissue Culture Techniques
2.
Neuroscience ; 156(3): 515-26, 2008 Oct 15.
Article in English | MEDLINE | ID: mdl-18765270

ABSTRACT

Transgenic mice with overexpression of the caspase-inhibitor, X-chromosome-linked inhibitor of apoptosis protein (XIAP) in Purkinje cell (PC) and in retinal bipolar cells (RBCs) were produced to study the regulation of cell death. Unexpectedly, an increased neurodegeneration was observed in the PCs in these L7-XIAP mice after the third postnatal week with the mice exhibiting severe ataxia. The loss of PCs was independent of Bax as shown by crossing the L7-XIAP mice with Bax gene-deleted mice. Electron microscopy revealed intact organelles in PCs but with the stacking of ER cisterns indicative of cell stress. Immunostaining for cell death proteins showed an increased phosphorylation of c-Jun in the PCs, suggesting an involvement in cell degeneration. Apart from PCs, the number of RBCs was decreased in adult retina in line with the expression pattern for the L7 promoter. The data show that overexpression of the anti-apoptotic protein XIAP in vulnerable neurons leads to enhanced cell death. The mechanisms underlying this neurodegeneration can be related to the effects of XIAP on cell stress and altered cell signaling.


Subject(s)
Gene Expression Regulation, Developmental/physiology , Nerve Degeneration/etiology , Purkinje Cells/metabolism , Retinal Bipolar Cells/metabolism , X-Linked Inhibitor of Apoptosis Protein/metabolism , Age Factors , Animals , Animals, Newborn , Ataxia/genetics , Behavior, Animal , Cerebellum/cytology , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum/pathology , Green Fluorescent Proteins/biosynthesis , Green Fluorescent Proteins/genetics , Humans , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microscopy, Electron, Scanning/methods , Nerve Degeneration/genetics , Nerve Degeneration/pathology , Phosphorylation , Proto-Oncogene Proteins c-jun/metabolism , Purkinje Cells/ultrastructure , Retinal Bipolar Cells/ultrastructure , Transfection/methods , X-Linked Inhibitor of Apoptosis Protein/genetics , bcl-2-Associated X Protein/deficiency
3.
Cell Mol Life Sci ; 61(7-8): 857-72, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15095008

ABSTRACT

The popularity of caffeine as a psychoactive drug is due to its stimulant properties, which depend on its ability to reduce adenosine transmission in the brain. Adenosine A(1) and A(2A) receptors are expressed in the basal ganglia, a group of structures involved in various aspects of motor control. Caffeine acts as an antagonist to both types of receptors. Increasing evidence indicates that the psychomotor stimulant effect of caffeine is generated by affecting a particular group of projection neurons located in the striatum, the main receiving area of the basal ganglia. These cells express high levels of adenosine A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the dopamine- and cyclic AMP-regulated 32-kDa phosphoprotein DARPP-32. The present review focuses on the effects of caffeine on striatal signal transduction and on their involvement in caffeine-mediated motor stimulation.


Subject(s)
Adenosine A1 Receptor Antagonists , Adenosine A2 Receptor Antagonists , Caffeine/metabolism , Caffeine/pharmacology , Central Nervous System Stimulants/metabolism , Motor Activity/drug effects , Nerve Tissue Proteins , Animals , Basal Ganglia/cytology , Basal Ganglia/metabolism , Dopamine/metabolism , Dopamine and cAMP-Regulated Phosphoprotein 32 , Enzyme Inhibitors/metabolism , Humans , Neurons/metabolism , Neuroprotective Agents/metabolism , Parkinson Disease/metabolism , Phosphoproteins/metabolism , Receptor, Adenosine A1/metabolism , Receptor, Adenosine A2A/metabolism , Receptors, Dopamine D2/metabolism , Signal Transduction , Synaptic Transmission/physiology
SELECTION OF CITATIONS
SEARCH DETAIL